The FDA has delayed its target decision date for Orca Bio’s blood cancer cell therapy candidate Orca-T by three months to ...
Johnson & Johnson bets $1B on a Pennsylvania cell therapy plant as earnings momentum, pipeline deals, and MedTech approvals ...
Thermo Fisher Scientific Inc., the world leader in serving science, today announced the global launch of the Gibco™ CTS™ ...
Officials at Caring Cross emphasize that the organization is dedicated to ensuring the global affordability of advanced therapies.
CEO Brian Culley highlighted the progress of OpRegen, noting its differentiation from current anti-complement therapies for dry AMD. He emphasized, “OpRegen has shown evidence of both anatomical and ...
Add Yahoo as a preferred source to see more of our stories on Google. FDA commissioner Marty Makary said eased manufacturing requirements for certain cell and gene therapies were “common-sense reforms ...
The "Cell and Gene Therapy Manufacturing Market -- Growth, Share, Opportunities & Competitive Analysis, 2024 -- 2032" report has been added to the Credence Research Inc. offering. The global Cell and ...
It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...
Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...
Rapid solar manufacturing expansion masks structural gaps, as heavy reliance on imported cells highlights imbalance in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results